| cAd3-Marburg Vaccine in Healthy Adults (NCT03475056) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-10-09 |
| Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects (NCT03613649) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-09-25 |
| A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults (NCT03603665) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-09-25 |
| Development of Childhood Anti-Influenza Immunity (NCT03673345) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-09-25 |
| Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals (NCT03571204) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-09-10 |
| Defining Skin Immunity of a Bite of Key Insect Vectors in Humans (NCT03641339) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-09-05 |
| 2013/2017 H7N9 Prime-Boost Interval (NCT03589807) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-08-21 |
| H3N2 M2SR in Pediatric Population (NCT03553940) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-08-15 |
| A Single Dose of Pembrolizumab in HIV-Infected People (NCT03367754) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-08-06 |
| Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy (NCT03208231) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-08-06 |
| Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult Volunteers (NCT03624790) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-31 |
| Safety and Pharmacokinetics Study of DM1157 to Treat Malaria (NCT03490162) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-31 |
| Tolerance by Engaging Antigen During Cellular Homeostasis (NCT03504241) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-30 |
| Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis (NCT03389893) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-25 |
| Cockroach Immunotherapy in Children and Adolescents (NCT03541187) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-16 |
| Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM (NCT03608774) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-13 |
| Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults (NCT03565315) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-10 |
| Clinical Study of a Single-Use, Point-of-Care Molecular Diagnostic Device for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) Utilizing Vaginal Swabs (NCT03596151) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-09 |
| Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults (NCT03611946) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-06 |
| Follow up of LEAP Participants and Their Families (NCT03546413) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-05 |
| Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum (NCT03386578) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-03 |
| Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents (NCT03332095) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-02 |
| Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology (NCT03366142) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-02 |
| Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates. (NCT03298334) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-01 |
| Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children (NCT03534245) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-01 |
| Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children (NCT03596801) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-06-29 |
| Sample Collection From Healthy Volunteers for Assay Optimization (NCT03538600) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-06-28 |
| Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) (NCT03538626) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-06-21 |
| Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults (NCT03408899) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-06-19 |
| Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA) (NCT03092505) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-06-15 |
| H5N1 With or Without Topical Aldara in Healthy Adults (NCT03472976) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-06-13 |
| The Mechanistic Biology of Primary Immunodeficiency Disorders (NCT03394053) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-05-30 |
| A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults (NCT03110757) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-05-20 |
| Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults (NCT03478891) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-05-16 |
| A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults (NCT03473002) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-05-16 |
| Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali (NCT03510481) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-05-14 |
| Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults (NCT03393468) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-05-10 |
| 2-5 Intermittent Caloric Restriction in HIV (NCT03489109) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-05-09 |
| Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors (NCT03382834) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-04-26 |
| Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine (NCT03058692) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-04-09 |
| Pretomanid in Adults With Hepatic Impairment (NCT02422524) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-03-29 |
| Minocycline Pharmacokinetics (ACUMIN) (NCT03369951) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-03-28 |
| Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults (NCT03409276) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-03-16 |
| Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein (NCT03462004) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-03-05 |
| Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults (NCT03387150) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-02-28 |
| Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 (NCT03318315) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-02-20 |
| Challenge Infection of Healthy Adult Volunteers With RSV A2 (NCT03388645) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-02-20 |
| Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly (NCT03312231) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-02-14 |
| A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051 (NCT03301090) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-02-12 |
| A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers (NCT03404167) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-02-02 |
| Community Dynamics of Malaria Transmission and Mosquito Feeding in Bancoumana, Mali (NCT03304704) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-01-28 |
| Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants (NCT03048422) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-01-19 |
| Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants (NCT03122223) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-01-16 |
| Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation Trial (NCT03374202) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-01-11 |
| Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States (NCT03382418) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-12-27 |
| JBT-101 in Systemic Lupus Erythematosus (SLE) (NCT03093402) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-12-21 |
| Age and Response to Flu Vaccines (NCT03328325) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-12-14 |
| Placebo-Controlled Trial of Antibiotic Therapy in Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin Level (NCT03341273) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-12-08 |
| Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up (NCT02431923) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-12-02 |
| Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant (NCT03330795) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-12-01 |
| Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge (NCT03416036) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-11-28 |
| A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children (NCT03292588) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-11-07 |
| Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women (NCT03164564) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-11-07 |
| PREDICT Cytomegalovirus (CMV) (NCT03300882) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-10-31 |
| An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab (NCT03167437) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-10-30 |
| Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (NCT03239483) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-10-26 |
| Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults (NCT03186781) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-10-25 |
| Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA (NCT03181789) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-10-18 |
| Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children (NCT03387137) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-10-13 |
| Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus (NCT03239470) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-10-10 |
| Targeted Microbiome Transplant in Atopic Dermatitis (NCT03151148) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-09-28 |
| Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age (NCT03227029) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-09-22 |
| Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV (NCT02906007) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-09-21 |
| Brentuximab Vedotin for Systemic Sclerosis (NCT03222492) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-09-20 |
| A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine (NCT03581903) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-09-19 |
| Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin (NCT03211156) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-09-11 |
| PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response (NCT03098862) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-09-04 |
| YCFM (Youth Correctional Facilities Males) (NCT03249935) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-08-24 |
| Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults (NCT03220724) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-08-22 |
| Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) (NCT03109288) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-08-11 |
| Novel Mobile Device Application to Improve Adherence (NCT02904278) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-08-10 |
| NIAID Centralized Sequencing Protocol (NCT03206099) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-07-31 |
| Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites (NCT03168854) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-07-26 |
| Impact of a Short-Term Analytical Treatment Interruption and Re-Initiation of Antiretroviral Therapy on Immunologic and Virologic Parameters in HIV-Infected Individuals (NCT03225118) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-07-17 |
| Using Biomarkers to Predict TB Treatment Duration (NCT02821832) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-06-21 |
| Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine (NCT03284710) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-06-19 |
| Atopic Dermatitis (AD) and Food Allergy (NCT03168113) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-06-12 |
| A Systems Biology Approach to Malaria Immunity (NCT03014258) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-06-07 |
| Dose Escalation PfSPZ-CVac (NCT03083847) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-06-05 |
| Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection (NCT02778204) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-06-05 |
| Phase I Trial of Measles Vectored Chikungungya Vaccine (NCT03028441) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-05-30 |
| Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers (NCT03035760) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-05-12 |
| Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults (NCT02840474) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-04-24 |
| Experimental Human Infection With Neisseria Gonorrhoeae (NCT03840811) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-04-23 |
| Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis (NCT03018275) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-04-20 |
| Screening for Alpha Thalassemia in Healthy Volunteers (NCT02692872) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-04-17 |
| Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age (NCT03102034) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-04-06 |
| Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults (NCT02996695) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-04-06 |
| VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents (NCT03110770) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-03-29 |
| CD8 Reactivity to Microorganisms in Blood and Breast Milk (NCT03084614) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-03-28 |